Switzerland has a nimbus of innovation and is known for its love of precision
In Conversation
Our aim is to produce Turkovac as soon as possible to inoculate the Turkish nation, and later send it to other countries, especially the ones that…
I see [market access] delays as a threat to Denmark’s ability to continue to attract international investment and clinical trials
A major global challenge is managing your data globally while keeping your data local
There are a lot of synergies to be leveraged between Allergan and AbbVie, all of which will help create a stronger overall organisation that can provide…
We are not interested in mass production products, rather focusing on niche generics where there are far more opportunities worldwide
As a Dane, I am very happy that Amgen has put a spotlight on Denmark, especially with the acquisitions that have been made over the last…
Having worked across Sweden, Norway, and Finland, I can say that, unfortunately, Denmark has become the most difficult Nordic market in which to launch new medications.…
Looking at Vision 2030, it is evident that the country's healthcare system is shifting to quality-based care which means that there will be improvements in efficiency,…
Having been used to battling against data separation and silos in the UK – where although the healthcare system is robust, the level of data integration…
The Saudi FDA and other authorities are advancing in the protection of innovation, helping not only to create better access to innovation, but also encouraging more…
Vision 2030 is creating greater stakeholder alignment, and making Saudi Arabia a more attractive destination for pharma industry investment, especially in clinical trials at this stage,…
